SV2009003407A - Azetidinas - Google Patents

Azetidinas

Info

Publication number
SV2009003407A
SV2009003407A SV2009003407A SV2009003407A SV2009003407A SV 2009003407 A SV2009003407 A SV 2009003407A SV 2009003407 A SV2009003407 A SV 2009003407A SV 2009003407 A SV2009003407 A SV 2009003407A SV 2009003407 A SV2009003407 A SV 2009003407A
Authority
SV
El Salvador
Prior art keywords
azetidins
antagonist
products
leiomiomes
endometriosis
Prior art date
Application number
SV2009003407A
Other languages
English (en)
Inventor
Kevin Neil Dack
Sarah Elizabeth Skerratt
Yeap Siew Kuen
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of SV2009003407A publication Critical patent/SV2009003407A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA CLASE DE AZETIDINAS ANTAGONISTAS DE EP2 DE FÓRMULA GENERAL (I): (VER FORMULA); EN LA QUE LAS VARIABLES Y SUSTITUYENTES SON COMO SE DEFINEN EN ESTE DOCUMENTO, Y ESPECIALMENTE A COMPUESTOS ANTAGONISTAS DE EP2, A SU USO EN MEDICINA, PARTICULARMENTE EN EL TRATAMIENTO DE ENDOMETRIOSIS Y/O MIOMAS UTERINOS (LEIOMIOMAS) Y A PRODUCTOS INTERMEDIOS ÚTILES EN SU SÍNTESIS Y A COMPOSICIONES QUE LOS CONTIENEN
SV2009003407A 2007-05-10 2009-11-06 Azetidinas SV2009003407A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91708107P 2007-05-10 2007-05-10
US1303007P 2007-12-12 2007-12-12

Publications (1)

Publication Number Publication Date
SV2009003407A true SV2009003407A (es) 2010-01-12

Family

ID=39739736

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2009003407A SV2009003407A (es) 2007-05-10 2009-11-06 Azetidinas

Country Status (27)

Country Link
US (1) US20080280877A1 (es)
EP (1) EP2155666A1 (es)
JP (1) JP2010526801A (es)
KR (1) KR20100009582A (es)
CN (1) CN101679235A (es)
AP (1) AP2009005047A0 (es)
AR (1) AR066524A1 (es)
AU (1) AU2008249744A1 (es)
BR (1) BRPI0811444A2 (es)
CA (1) CA2686517A1 (es)
CL (1) CL2008001305A1 (es)
CO (1) CO6260066A2 (es)
CR (1) CR11101A (es)
DO (1) DOP2009000256A (es)
EA (1) EA200901381A1 (es)
EC (1) ECSP099727A (es)
GT (1) GT200900293A (es)
IL (1) IL201874A0 (es)
MA (1) MA31366B1 (es)
MX (1) MX2009011998A (es)
PA (1) PA8779601A1 (es)
PE (1) PE20090282A1 (es)
SV (1) SV2009003407A (es)
TN (1) TN2009000470A1 (es)
TW (1) TW200904409A (es)
UY (1) UY31070A1 (es)
WO (1) WO2008139287A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009063365A1 (en) * 2007-11-15 2009-05-22 Pfizer Limited Azetidines as ep2 antagonists
CN102209710A (zh) * 2008-11-10 2011-10-05 辉瑞股份有限公司 吡咯烷类化合物
CA2757480A1 (en) * 2009-04-02 2010-10-07 Allergan, Inc. Prostaglandin e receptor antagonists
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
TWI589576B (zh) * 2011-07-15 2017-07-01 諾華公司 氮雜-雙環二芳基醚之鹽類及製造彼等或其前驅物之方法
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ep2受體拮抗劑之新穎2h-吲唑
JP2017538769A (ja) 2014-12-22 2017-12-28 ファイザー・インク プロスタグランジンep3受容体の拮抗薬
CN110041269A (zh) * 2019-05-16 2019-07-23 海门瑞一医药科技有限公司 一种2-氯-5-羟基嘧啶的制备方法
JP2024524981A (ja) * 2021-06-24 2024-07-09 レザボア ニューロサイエンス,インコーポレイテッド Ep2アンタゴニスト化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8300860D0 (en) * 1983-01-13 1983-02-16 Shell Int Research Azetidine compounds
GB8415614D0 (en) * 1984-06-19 1984-07-25 Shell Int Research Azetidine derivatives
GB8509746D0 (en) * 1985-04-16 1985-05-22 Shell Int Research Preparing azetidine derivatives
AR037364A1 (es) 2001-11-16 2004-11-03 Schering Corp Azetidinil diaminas utiles como ligandos del receptor de nociceptina orl-1
EP1934174B1 (en) * 2005-10-07 2011-04-06 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
US8383660B2 (en) * 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives

Also Published As

Publication number Publication date
ECSP099727A (es) 2009-12-28
GT200900293A (es) 2010-05-17
CN101679235A (zh) 2010-03-24
EP2155666A1 (en) 2010-02-24
US20080280877A1 (en) 2008-11-13
CL2008001305A1 (es) 2008-07-18
MA31366B1 (fr) 2010-05-03
PE20090282A1 (es) 2009-03-27
TN2009000470A1 (fr) 2011-03-31
BRPI0811444A2 (pt) 2014-10-29
DOP2009000256A (es) 2009-11-30
IL201874A0 (en) 2010-06-16
MX2009011998A (es) 2009-11-19
JP2010526801A (ja) 2010-08-05
PA8779601A1 (es) 2009-01-23
UY31070A1 (es) 2009-01-05
AR066524A1 (es) 2009-08-26
CR11101A (es) 2009-12-04
AP2009005047A0 (en) 2009-12-31
WO2008139287A1 (en) 2008-11-20
CO6260066A2 (es) 2011-03-22
AU2008249744A1 (en) 2008-11-20
CA2686517A1 (en) 2008-11-20
KR20100009582A (ko) 2010-01-27
TW200904409A (en) 2009-02-01
EA200901381A1 (ru) 2010-06-30

Similar Documents

Publication Publication Date Title
SV2009003407A (es) Azetidinas
CY1125061T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει δροσπιρενονη για χρηση ως ενα αντισυλληπτικο
SV2018005791A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
CY1117878T1 (el) Πυριδινo-2-αμιδια χρησιμα ως αγωνιστες του cb2
CL2017002332A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
CY1115673T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν 2-οξο-1-πυρρολιδινο παραγωγα
PE20151067A1 (es) Inhibidores de autotaxina
CY1117441T1 (el) Αρυλοαιθινυλο παραγωγα
CR20120264A (es) Compuestos
CY1114988T1 (el) Βενζοδιαζεπινη αναστολεας bromodomain
CR20110579A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
GT201300236A (es) Derivados de pirrolo (2,3-d) pirimidina como inhibidores de quinasa relacionados con tropomiosina
CL2013002299A1 (es) Compuestos derivados de heterociclos, inhibidores de la replicacion del virus de la hepatitis c; composicion farmaceutica que los comprende; util en el tratamiento de una infeccion por vhc. (divisional solicitud 689-2011).
CL2012001821A1 (es) Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
PA8815201A1 (es) Compuestos heterociclicos
CL2011001967A1 (es) Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico.
CY1115994T1 (el) Φαρμακευτικες τυποποιησεις οι οποιες περιεχουν προσδεματα υποδοχεα ντοπαμινης
CU20160007A7 (es) Derivados de 2((( oxadiazol/triazol/tetrazol/isoxazol) metil) fenil)-1-(heterociclil)-ona como inhibidores activos de autotaxina
CL2013003527A1 (es) Compuestos heterociclicos antagonistas de los receptores muscarinicos y agonistas del receptor beta2 adrenergico; su composicion farmaceutica; su combinacion; un dispositivo y su uso en la prevencion y/o el tratamiento de enfermedades bronco-obstructivas o inflamatorias como asma y epoc.
GT201300254A (es) Triazolopiridinas
CR20130569A (es) Análogos del ácido epoxieicosatrienoicos y métodos de toma y uso del mismo
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
MX2011007451A (es) Composiciones farmaceuticas que comprenden derivados de 2-oxo-1 pirrolidina.
CO6351723A2 (es) Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1
CY1122381T1 (el) Παραγωγα ιμιδαζοπυριδαζινης ως αναστολεις pi3kbhta

Legal Events

Date Code Title Description
FD Lapse